8 results about "Tetanus toxoids" patented technology

The present invention relates to the field of vaccines, and in particular to a novel adjuvant polypeptide sequence and a use thereof. The adjuvant polypeptide sequence provided by the present invention comprises amino acid sequences of tetanus toxoid epitopes P2 and P16 and further comprises amino acid sequences of P30 and / or PX. The adjuvant polypeptide sequence aims to expand the coverage population of immune responses by increasing epitope diversity. In addition, the present invention uses an LNP (lipid nanoparticle) delivery system to introduce an mRNA encoding an adjuvant polypeptide and an initial antigen protein into a human body, thereby improving the immunostimulatory ability of the initial antigen. The adjuvant polypeptide sequence provided by the present invention and the initial antigen sequence are preferably fused, thereby simplifying the composition of mRNA in a nucleic acid vaccine and reducing the complexity of vaccine preparation.

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

The present invention discloses a pharmaceutical composition, its manufacturing method, and its use, wherein the pharmaceutical composition comprises a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient, the first active ingredient being a microbial agent containing one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, or Salmonella paratyphi, and the second active ingredient comprising polyinosinic acid, polycytidylic acid, and vitamins. The pharmaceutical composition is an artificial active immunotherapy for tumors, which, by "stimulating" the entire immune system, activates the human immune system using bacteria to kill cancer cells, making the treatment extremely stable and reliable, significantly saving and extending the lives of cancer patients, while simultaneously being extremely safe, having very few toxic side effects, and having low manufacturing costs.

Disclosed herein are clostridial neurotoxin (BoNT) and tetanus neurotoxin (TeNT), polypeptides, fragments and / or variants, compositions, polynucleotides, vaccines, and conjugate vaccine platforms, and methods of using the BoNT and TeNT, polypeptides, and fragments.

The present invention relates to a composition comprising a first PEGylated tetanus neurotoxin (PEG-TeNT) comprising tetanus neurotoxin (TeNT) conjugated to polyethylene glycol (PEG) and a second TeNT. The present invention also relates to various PEG-TeNTs. The invention also relates to methods of treating hypotonia using the compositions or various PEG-TeNTs, and kits comprising the compositions or various PEG-TeNTs. In one embodiment, the hypotonia is obstructive sleep apnea.SOLUTION: The present inventors have created a family of modified TeNTs and treatment regimens to address these issues.SELECTED DRAWING: Figure 1

This invention discloses a tetanus vaccine and its enzyme-linked immunosorbent assay (ELISpot) analysis method. The tetanus vaccine of this invention is designed based on screened tetanus antigen peptides, which contain any of the amino acid sequences shown in SEQ ID NO:1-SEQ ID NO:61. Addressing the technical problem of the lack of specific T-cell immune response detection methods for existing tetanus vaccines, this invention designs an overlapping peptide library covering the entire sequence of tetanus toxoid, screening out dominant peptides that can effectively stimulate T-cell responses, significantly improving the sensitivity and specificity of detection. This method optimizes the processing flow of PBMCs in the test samples, establishes a quantitative analysis standard based on IFN-γ secretion, and achieves accurate assessment of the T-cell immune response induced by the tetanus vaccine.

The invention relates to the field of vaccines, in particular to a novel adjuvant polypeptide sequence and application thereof. The polypeptide sequence of the adjuvant provided by the invention comprises tetanus toxoid epitope P2 and P16 amino acid sequences, and further comprises P30 and / or PX amino acid sequences. The polypeptide sequence of the adjuvant aims to expand the coverage population of immune response by increasing the diversity of epitopes. Meanwhile, an LNP (Lipid Nanoparticle) delivery system is utilized to efficiently introduce mRNA (Messenger Ribonucleic Acid) encoding adjuvant polypeptide and initial antigen protein into a body, so that the immunostimulation ability of the initial antigen is effectively improved, and the immune effect of a traditional dosage can still be achieved or exceeded while the use dosage of the initial antigen is reduced. Furthermore, the polypeptide sequence and the initial antigen sequence of the adjuvant provided by the invention preferably adopt a fusion mode, so that the composition of mRNA (messenger ribonucleic acid) in the nucleic acid vaccine is simplified, the complexity of vaccine preparation is reduced, a new idea is provided for vaccine process development, and the adjuvant has remarkable technical progress and clinical application potential.

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.